Published in J Hypertens on December 01, 2006
Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension (2008) 1.30
Racial differences in nitric oxide-dependent vasorelaxation. Reprod Sci (2008) 0.92
An NOS3 Haplotype is Protective against Hypertension in a Caucasian Population. Int J Hypertens (2010) 0.89
Endothelial nitric oxide synthase gene polymorphisms and the risk of hypertension in an Indian population. Biomed Res Int (2014) 0.86
eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2012) 0.82
The effects of endothelial nitric oxide synthase tagSNPs on nitrite levels and risk of hypertension and obesity in children and adolescents. J Hum Hypertens (2014) 0.78
Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study. BMC Cardiovasc Disord (2009) 0.78
Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457. Int J Clin Exp Pathol (2015) 0.76
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med (2002) 7.59
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target. Basic Clin Pharmacol Toxicol (2012) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2015) 2.03
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A (2004) 1.68
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med (2002) 1.64
Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med (2006) 1.63
Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med (2007) 1.60
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest (2015) 1.55
Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism. Crit Care Med (2011) 1.53
Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med (2009) 1.52
Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats. Cardiovasc Drugs Ther (2013) 1.52
Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis (2006) 1.51
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med (2006) 1.49
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Elevated plasma hemoglobin levels increase nitric oxide consumption in experimental and clinical acute pulmonary thromboembolism. Crit Care Med (2013) 1.42
The white coat effect is not associated with additional increase of target organ damage in true resistant hypertension. Med Clin (Barc) (2012) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist (2006) 1.30
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum (2004) 1.25
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat (2008) 1.21
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy (2010) 1.21
Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging (2012) 1.20
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol (2010) 1.18
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17
Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study. Crit Care (2012) 1.16
Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol (2006) 1.16
Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis (2007) 1.15
Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol (2003) 1.15
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension (2008) 1.14
Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem (2006) 1.13
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer (2007) 1.10
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev (2012) 1.10
In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos (2010) 1.10
Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther (2004) 1.09
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity. Diabetes Metab Syndr Obes (2011) 1.09
Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer (2006) 1.08
Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide (2005) 1.08
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother (2008) 1.08
Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07
Cardiovascular effects of partial sleep deprivation in healthy volunteers. J Appl Physiol (1985) (2012) 1.07
Resistant hypertension revisited: definition and true prevalence. J Hypertens (2014) 1.06
Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension. Free Radic Biol Med (2011) 1.05
Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med (2009) 1.05
Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. Circulation (2013) 1.05
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat (2006) 1.04